A director of molecular pathology at a U.S. reference lab conducts NGS on clinical samples as well as for pharma sponsored research. They utilize Illumina and ThermoFisher instruments and are interested in evaluating Oxford Nanopore and PacBio in the future. ThermoFisher is their preferred vendor given the ease that the end-to-end system brings to their lab. They think regulatory hurdles and reimbursement create some difficulties for using NGS on some patient samples. Other key NGS pain points for clinical samples include sample input, throughput, and bioinformatics. When considering adoption of new instruments, they look at clinical utility, sensitivity and specificity, ease of use, and cost. If new vendors can show this is comparable to or better than Illumina, then they will consider adopting. They predict that their NGS infrastructure spend will increase 20-30% over the next year as samples increase.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.